01 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Prima BioMed has commenced recruitment of patients into the Canvas (Cancer Vaccine Study) trial in Europe. Prima has authorized several centers in Ukraine to start enrolling patients.
Canvas is a phase II/III study of CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy.
Prima has obtained the requisite ethics and regulatory approvals in multiple European countries, including Belarus, Belgium, Bulgaria, Germany, Lithuania, Latvia, Poland and Ukraine. The company anticipates that the majority of Canvas patients will be enrolled in Europe. The trial is currently open for recruitment at a number of centers in the US and Australia.
Prima BioMed CEO Mr Matthew Lehman said, "We are pleased to open enrollment for the CANVAS trial in Europe; we plan to progressively open sites across several European countries in the coming months. I would like to congratulate our clinical team and our manufacturing colleagues at the Fraunhofer Institute of Cell Therapy and Immunology for bringing us to this milestone."